<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">PLoS One</journal-id>
      <journal-id journal-id-type="publisher-id">plos</journal-id>
      <journal-id journal-id-type="pmc">plosone</journal-id>
      <journal-title-group>
        <journal-title>PLoS ONE</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1932-6203</issn>
      <publisher>
        <publisher-name>Public Library of Science</publisher-name>
        <publisher-loc>San Francisco, USA</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">22235272</article-id>
      <article-id pub-id-type="pmc">3250427</article-id>
      <article-id pub-id-type="publisher-id">PONE-D-11-20129</article-id>
      <article-id pub-id-type="doi">10.1371/journal.pone.0029205</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Research Article</subject>
        </subj-group>
        <subj-group subj-group-type="Discipline-v2">
          <subject>Biology</subject>
          <subj-group>
            <subject>Computational Biology</subject>
            <subj-group>
              <subject>Genomics</subject>
            </subj-group>
            <subj-group>
              <subject>Population Genetics</subject>
            </subj-group>
          </subj-group>
          <subj-group>
            <subject>Evolutionary Biology</subject>
            <subj-group>
              <subject>Evolutionary Processes</subject>
            </subj-group>
            <subj-group>
              <subject>Population Genetics</subject>
            </subj-group>
          </subj-group>
          <subj-group>
            <subject>Genetics</subject>
            <subj-group>
              <subject>Genetic Mutation</subject>
            </subj-group>
            <subj-group>
              <subject>Population Genetics</subject>
            </subj-group>
          </subj-group>
          <subj-group>
            <subject>Genomics</subject>
          </subj-group>
          <subj-group>
            <subject>Population Biology</subject>
            <subj-group>
              <subject>Population Genetics</subject>
            </subj-group>
          </subj-group>
        </subj-group>
        <subj-group subj-group-type="Discipline-v2">
          <subject>Medicine</subject>
          <subj-group>
            <subject>Endocrinology</subject>
            <subj-group>
              <subject>Diabetic Endocrinology</subject>
            </subj-group>
          </subj-group>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Permanent Neonatal Diabetes Caused by Creation of an Ectopic Splice Site within the <italic>INS</italic> Gene</article-title>
        <alt-title alt-title-type="running-head">Neonatal Diabetes Caused by Intronic <italic>INS</italic> Mutation</alt-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" equal-contrib="yes">
          <name>
            <surname>Garin</surname>
            <given-names>Intza</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" equal-contrib="yes">
          <name>
            <surname>Perez de Nanclares</surname>
            <given-names>Guiomar</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Gastaldo</surname>
            <given-names>Elena</given-names>
          </name>
          <xref ref-type="aff" rid="aff3">
            <sup>3</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Harries</surname>
            <given-names>Lorna W.</given-names>
          </name>
          <xref ref-type="aff" rid="aff4">
            <sup>4</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Rubio-Cabezas</surname>
            <given-names>Oscar</given-names>
          </name>
          <xref ref-type="aff" rid="aff5">
            <sup>5</sup>
          </xref>
          <xref ref-type="aff" rid="aff6">
            <sup>6</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Casta&#xF1;o</surname>
            <given-names>Luis</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
          <xref ref-type="corresp" rid="cor1">
            <sup>*</sup>
          </xref>
        </contrib>
      </contrib-group>
      <aff id="aff1">
        <label>1</label>
        <addr-line>Endocrinology and Diabetes Research Group, Hospital de Cruces, Universitat Polit&#xE8;cnica de Val&#xE8;ncia/Euskal Herriko Unibertsitateko, Barakaldo, Bizkaia, Spain</addr-line>
      </aff>
      <aff id="aff2">
        <label>2</label>
        <addr-line>Centro de Investingaci&#xF3;n Biom&#xE8;dica en Red de Diabetes y Endermedades Metab&#xF3;licas (CIBERDM), Centro de investigaci&#xF3;n Biom&#xE8;dica en Red de Endermedads Raras (CIBERER), Barakaldo, Bizkaia, Spain</addr-line>
      </aff>
      <aff id="aff3">
        <label>3</label>
        <addr-line>Pediatric Endocrinology, Hospital de La Ribera, Alzira, Valencia, Spain</addr-line>
      </aff>
      <aff id="aff4">
        <label>4</label>
        <addr-line>Institute of Biomedical and Clinical Science, Peninsula College of Medicine and Dentistry, Exeter, United Kingdom</addr-line>
      </aff>
      <aff id="aff5">
        <label>5</label>
        <addr-line>Department of Pediatric Endocrinology, Hospital Infantil Universitario Ni&#xF1;o Jes&#xFA;s, Madrid, Spain</addr-line>
      </aff>
      <aff id="aff6">
        <label>6</label>
        <addr-line>Centro de Investigaci&#xF3;n Biom&#xE9;dica en Red Fisiopatog&#xED;a se la obesidad y Nutrici&#xF3;n, Instituto de Salud Carlos III, Madrid, Spain</addr-line>
      </aff>
      <contrib-group>
        <contrib contrib-type="editor">
          <name>
            <surname>Veitia</surname>
            <given-names>Reiner Albert</given-names>
          </name>
          <role>Editor</role>
          <xref ref-type="aff" rid="edit1"/>
        </contrib>
      </contrib-group>
      <aff id="edit1">Institut Jacques Monod, France</aff>
      <author-notes>
        <corresp id="cor1">* E-mail: <email>lcastano@osakidetza.net</email></corresp>
        <fn fn-type="con">
          <p>Conceived and designed the experiments: IG GPN LWH. Performed the experiments: IG. Analyzed the data: IG GPN ORC LC. Contributed reagents/materials/analysis tools: EG LC. Wrote the paper: IG GPN ORC LWH LC.</p>
        </fn>
      </author-notes>
      <pub-date pub-type="collection">
        <year>2012</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>3</day>
        <month>1</month>
        <year>2012</year>
      </pub-date>
      <volume>7</volume>
      <issue>1</issue>
      <elocation-id>e29205</elocation-id>
      <history>
        <date date-type="received">
          <day>7</day>
          <month>10</month>
          <year>2011</year>
        </date>
        <date date-type="accepted">
          <day>22</day>
          <month>11</month>
          <year>2011</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Garin et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</copyright-statement>
        <copyright-year>2012</copyright-year>
      </permissions>
      <abstract>
        <sec>
          <title>Background</title>
          <p>The aim of this study was to characterize the genetic etiology in a patient who presented with permanent neonatal diabetes at 2 months of age.</p>
        </sec>
        <sec>
          <title>Methodology/Principal Findings</title>
          <p>Regulatory elements and coding exons 2 and 3 of the <italic>INS</italic> gene were amplified and sequenced from genomic and complementary DNA samples.</p>
          <p>A novel heterozygous <italic>INS</italic> mutation within the terminal intron of the gene was identified in the proband and her affected father. This mutation introduces an ectopic splice site leading to the insertion of 29 nucleotides from the intronic sequence into the mature mRNA, which results in a longer and abnormal transcript.</p>
        </sec>
        <sec>
          <title>Conclusions/Significance</title>
          <p>This study highlights the importance of routinely sequencing the exon-intron boundaries and the need to carry out additional studies to confirm the pathogenicity of any identified intronic genetic variants.</p>
        </sec>
      </abstract>
      <counts>
        <page-count count="5"/>
      </counts>
    </article-meta>
  </front>
  <body>
    <sec id="s1">
      <title>Introduction</title>
      <p>Neonatal diabetes mellitus is a rare genetic disorder (1&#x2236;100,000 live newborns) characterized by hyperglycemia and low insulin levels presenting during the first 6 months of life <xref ref-type="bibr" rid="pone.0029205-Russo1">[1]</xref>. The disease can be clinically subdivided into transient (TNDM) and permanent (PNDM) forms depending on whether or not insulin dependence resolves in infancy.</p>
      <p>In the last few years, a number of mutations in the preproinsulin gene (<italic>INS</italic>) (summarized by Stoy et al) <xref ref-type="bibr" rid="pone.0029205-Stoy1">[2]</xref> have been found to be the second most common cause of PNDM (12% according to Edghill et al. and 24.3% according to Colombo et al.) <xref ref-type="bibr" rid="pone.0029205-Edghill1">[3]</xref>, <xref ref-type="bibr" rid="pone.0029205-Colombo1">[4]</xref>.</p>
      <p>Initially, heterozygous coding mutations were identified <xref ref-type="bibr" rid="pone.0029205-Russo1">[1]</xref>, <xref ref-type="bibr" rid="pone.0029205-Edghill1">[3]</xref>&#x2013;<xref ref-type="bibr" rid="pone.0029205-Polak1">[7]</xref>. These mutations show a dominant inheritance and most of them have been found to disrupt the folding and conformation of proinsulin <italic>in vitro</italic>, thus inducing endoplasmatic reticulum (ER) stress <xref ref-type="bibr" rid="pone.0029205-Colombo1">[4]</xref>. Clinical features of these patients suggest that birth weight is similar <xref ref-type="bibr" rid="pone.0029205-Edghill1">[3]</xref> or slightly higher <xref ref-type="bibr" rid="pone.0029205-Colombo1">[4]</xref> compared to birth weight in patients with mutations in <italic>KCNJ11</italic> and <italic>ABCC8</italic>, although patients with heterozygous mutations in the <italic>INS</italic> gene tend to be diagnosed slightly later <xref ref-type="bibr" rid="pone.0029205-Stoy1">[2]</xref>&#x2013;<xref ref-type="bibr" rid="pone.0029205-Colombo1">[4]</xref>.</p>
      <p>Subsequently, recessively-acting biallelic <italic>INS</italic> mutations were described which result in decreased insulin biosynthesis through distinct mechanisms, including gene deletion, abnormal transcription, lack of the translation initiation signal, and altered mRNA stability. Compared to patients carrying heterozygous <italic>INS</italic> mutations, patients with biallelic <italic>INS</italic> mutations show a markedly different clinical phenotype, with lower birth weight (median: 1680 g vs 2530 g) and an earlier age at diagnosis (median: 1 week vs 10 weeks) <xref ref-type="bibr" rid="pone.0029205-Garin1">[8]</xref>, <xref ref-type="bibr" rid="pone.0029205-Raile1">[9]</xref>.</p>
      <p>We report the identification of a PNDM patient carrying a heterozygous mutation within the terminal intron of the <italic>INS</italic> gene. The mutation results in aberrant splicing by introducing an ectopic splice site leading to the insertion of 29 nucleotides from the intron into the mature mRNA and therefore resulting in a longer and abnormal transcript.</p>
    </sec>
    <sec id="s2">
      <title>Results and Discussion</title>
      <p>Since the first description of <italic>INS</italic> as a PNDM gene in 2007, several dominantly-acting mutations (23 missense, one nonsense, one insertion/deletion) <xref ref-type="bibr" rid="pone.0029205-Stoy1">[2]</xref> and a further ten recessively-acting mutations have been reported to cause neonatal diabetes <xref ref-type="bibr" rid="pone.0029205-Garin1">[8]</xref>. They are located in all regions of the preproinsulin gene, including the promoter (6 mutations), signal peptide (3 mutations), B-chain (12 mutations), C-peptide (2 mutations), A-chain (8 mutations), and both pairs of basic amino acids flanking the C-peptide (2 mutations) <xref ref-type="bibr" rid="pone.0029205-Stoy1">[2]</xref>. <italic>In vitro</italic> studies for some of these mutations have confirmed <xref ref-type="bibr" rid="pone.0029205-Colombo1">[4]</xref>, <xref ref-type="bibr" rid="pone.0029205-Park1">[10]</xref>, <xref ref-type="bibr" rid="pone.0029205-Meur1">[11]</xref> or discarded <xref ref-type="bibr" rid="pone.0029205-Liu1">[12]</xref> their pathogenic effect, thus highlighting the importance <italic>in vitro</italic> studies for the functional characterization of genetic variants identified in rare diseases, where familial co-segregation studies cannot usually be performed since there is often one affected individual at each family.</p>
      <p>On the other side, no intronic <italic>INS</italic> mutation affecting splicing has been described to date. The majority of splicing-disrupting mutations detected in other genes are single nucleotide substitutions within the consensus sequence of the splice sites and result in either complete exon skipping, use of a nearby pseudo 3&#x2032; or 5&#x2032; splice site, or retention of the mutated intron <xref ref-type="bibr" rid="pone.0029205-Faustino1">[13]</xref>. Less frequently, the mutations create an ectopic splice site or activate a cryptic splice site, thereby changing the overall splicing pattern of the mutant transcript <xref ref-type="bibr" rid="pone.0029205-Cartegni1">[14]</xref>.</p>
      <p>In the present study, we have identified the first heterozygous intronic mutation (c.188-31G&gt;A) in the <italic>INS</italic> gene causing neonatal diabetes in both the proband and her affected father (<xref ref-type="fig" rid="pone-0029205-g001">Figure 1</xref>). The variant is located 31 bp proximal to exon 3 within the polypyrimidine tract of intron 2, which normally determines the strength of the splice acceptor site. The mutation turns the dinucleotide (Y)<sub>n</sub><bold>G</bold>G into (Y)<sub>n</sub><bold>A</bold>G, creating a typical consensus 3&#x2032; splice site, as <italic>in silico</italic> analysis predicted. Indeed, the confidence value for the new ectopic splice site was higher than that for the regular splice site (0.52 vs 0.18) so that the splicing machinery would preferentially recognise the new splice site and read the last 29 bp of intron 2 as exonic sequence (<xref ref-type="fig" rid="pone-0029205-g002">Figure 2</xref>).</p>
      <fig id="pone-0029205-g001" position="float">
        <object-id pub-id-type="doi">10.1371/journal.pone.0029205.g001</object-id>
        <label>Figure 1</label>
        <caption>
          <title>Partial pedigree of the family with intronic INS mutation.</title>
          <p>(N, Normal allele; M, mutation). Solid black-filled shapes represent patients with permanent neonatal diabetes. Age at diagnosis and birth weight are shown below the symbols (NA: not available).</p>
        </caption>
        <graphic xlink:href="pone.0029205.g001"/>
      </fig>
      <fig id="pone-0029205-g002" position="float">
        <object-id pub-id-type="doi">10.1371/journal.pone.0029205.g002</object-id>
        <label>Figure 2</label>
        <caption>
          <title>Schematic representation of the intron-exon structure of the INS gene and the splicing changes due to the found mutation.</title>
          <p>Exons are represented by white boxes, introns as lanes, the intronic insertion at transcript level is indicated by a grey box and the new aberrant sequence is shown in black. The splicing event is shown by a broken lane. The mutation position is indicated in red. Y: C/T.</p>
        </caption>
        <graphic xlink:href="pone.0029205.g002"/>
      </fig>
      <p>RNA studies carried out on a lymphoblastoid cell line obtained from the proband confirmed this hypothesis (<xref ref-type="fig" rid="pone-0029205-g003">Figure 3</xref>). The 29 bp insertion alters the reading frame in the mutant transcript which is not predicted to be subject to nonsense-mediated <xref ref-type="bibr" rid="pone.0029205-Silva1">[15]</xref> nor non-stop decay <xref ref-type="bibr" rid="pone.0029205-Vasudevan1">[16]</xref> since the frame shift would not generate a premature termination codon and the new stop codon would be located within the 3&#x2032; UTR (19 aminoacids downstream the original stop codon). In fact, according to the intensity of the bands obtained after RT-PCR (results not shown), the mutant transcript was processed more efficiently than the normal transcript, as predicted by <italic>in silico</italic> studies. The mutant proprotein would normally translocate into the ER as the signal peptide is intact. <italic>In silico</italic> 3D structure studies of its amino acid sequence (p.Val63Glufs*78) predicted the removal of the three conserved disulfide bonds (B7-A7, B19-A20, A6-A11) and the creation of a new one (B19-N25), suggesting that mutant protein would fail to fold properly (<xref ref-type="fig" rid="pone-0029205-g004">Figures 4</xref> and <xref ref-type="fig" rid="pone-0029205-g005">5</xref>). However, the B-chain would be normal and Arg31,32 cleavage site remains accessible (<xref ref-type="fig" rid="pone-0029205-g006">Figure 6</xref>).</p>
      <fig id="pone-0029205-g003" position="float">
        <object-id pub-id-type="doi">10.1371/journal.pone.0029205.g003</object-id>
        <label>Figure 3</label>
        <caption>
          <title>Sequence of amplified cDNA obtained from RNA of lymphoblastoid cells.</title>
          <p>Upper sequence is obtained from patient's immortalized cells. Lower panel, the sequence obtained from unaffected control lymphoblastoid cells.</p>
        </caption>
        <graphic xlink:href="pone.0029205.g003"/>
      </fig>
      <fig id="pone-0029205-g004" position="float">
        <object-id pub-id-type="doi">10.1371/journal.pone.0029205.g004</object-id>
        <label>Figure 4</label>
        <caption>
          <title>Tertiary structure of the wild-type proinsulin (PDB ref: 2KQP).</title>
          <p>Disulfide bonds (B7-A7, B19-A20, A6-A11) are shown in green.</p>
        </caption>
        <graphic xlink:href="pone.0029205.g004"/>
      </fig>
      <fig id="pone-0029205-g005" position="float">
        <object-id pub-id-type="doi">10.1371/journal.pone.0029205.g005</object-id>
        <label>Figure 5</label>
        <caption>
          <title>Predicted tertiary structure of the aberrant protein.</title>
          <p>The new disulfide bond (B19-N25) is shown in green. Unpaired cysteine residues (B7 and N34) are shown in cyan. N25 and N34: cysteine at position 25 and 34 of the &#x201C;new&#x201D; aminoacidic sequence. N34 correspond to Cys72.</p>
        </caption>
        <graphic xlink:href="pone.0029205.g005"/>
      </fig>
      <fig id="pone-0029205-g006" position="float">
        <object-id pub-id-type="doi">10.1371/journal.pone.0029205.g006</object-id>
        <label>Figure 6</label>
        <caption>
          <title>Superposition of both proteins.</title>
          <p>Arg31,32 cleavage site is shown in yellow in both the normal and mutant chains.</p>
        </caption>
        <graphic xlink:href="pone.0029205.g006"/>
      </fig>
      <p>Although it has not yet been established clearly the sequence of events leading to initiation of B-chain folding, formation of inter- and intrachain disulfide bond and proinsulin cleavage, misfolding would disrupt trafficking from the endoplasmic reticulum which would ultimately lead to &#x3B2;-cell dysfunction and eventual cell death <xref ref-type="bibr" rid="pone.0029205-Liu2">[17]</xref>, as it happens with a number of other previously described heterozygous <italic>INS</italic> mutations <xref ref-type="bibr" rid="pone.0029205-Stoy1">[2]</xref>.</p>
      <p>Clinically, the birth weight of the proband was normal. Although birth weight in patients carrying <italic>INS</italic> heterozygous coding mutations tend to be low <xref ref-type="bibr" rid="pone.0029205-Stoy1">[2]</xref>, some cases with normal birth weight have been reported <xref ref-type="bibr" rid="pone.0029205-Colombo1">[4]</xref>. It has been proposed that the growth retardation at birth might be partly explained by the gender of the patient, being more severe in males than in females <xref ref-type="bibr" rid="pone.0029205-Fendler1">[18]</xref>. In our experience, however, low birth weight is usually associated with recessively-inherited <italic>INS</italic> mutations that lead to a nearly complete insulin deficiency <xref ref-type="bibr" rid="pone.0029205-Garin1">[8]</xref>, whereas heterozygous mutations leading to a gradual and progressive decrease of insulin secretion secondary to ER stress-mediated &#x3B2;-cell apoptosis are associated with normal or slightly reduced birth weight <xref ref-type="bibr" rid="pone.0029205-Edghill1">[3]</xref>&#x2013;<xref ref-type="bibr" rid="pone.0029205-Stoy2">[5]</xref>. The proband was diagnosed at 5 weeks of age, slightly earlier that the reported median age of 10 weeks <xref ref-type="bibr" rid="pone.0029205-Stoy1">[2]</xref>, <xref ref-type="bibr" rid="pone.0029205-Edghill1">[3]</xref>, but this may reflect an increased awareness due to the positive family history.</p>
      <p>In summary, we report a novel mutation type at the preproinsulin gene leading to neonatal diabetes. Our finding highlights the importance of routinely sequencing exon-intron boundaries and the need to carry out additional RNA studies to confirm the pathogenicity of any identified intronic genetic variants.</p>
    </sec>
    <sec sec-type="materials|methods" id="s3">
      <title>Materials and Methods</title>
      <sec id="s3a">
        <title>Ethics statement</title>
        <p>The study was carried out in accordance with the Declaration of Helsinki. This study was approved by the Medical Ethics Commission, Hospital de Cruces. The study also complied with Spanish laws and regulations, accreditation standards and institutional policies. Participants gave written informed consent, with parents consenting on behalf of the proband.</p>
      </sec>
      <sec id="s3b">
        <title>Case report</title>
        <p>The proband, of Caucasian origin, presented with permanent diabetes at 2 months of age (blood glucose 8.3&#x2013;10 mmol/L). She was born to non-consanguineous parents at 40 weeks gestation with a normal birth weight (3050 g, &#x2212;0.66 SDS). Pregnancy was uneventful. Pancreatic autoantibodies (ICA and IAA) were absent at diagnosis and she was started on subcutaneous insulin (initial daily requirement 0.4 U/kg). There was a strong family history of early-onset diabetes on the paternal side. Her father was diagnosed with permanent neonatal diabetes (PNDM) at 31 days of life and two paternal aunts died from diabetic ketoacidosis within the first year. The proband is currently 10.5 years and remains on intensive insulin therapy (1.1 U/kg/day). Diabetes has never remitted.</p>
      </sec>
      <sec id="s3c">
        <title>Molecular genetic analysis</title>
        <p>Genomic DNA from proband and parents was extracted from peripheral leukocytes using standard procedures using QIAamp DNA Mini Kit (QIAGEN, D&#xFC;ren, Germany). Regulatory elements and coding exons 2 and 3 of the <italic>INS</italic> gene were amplified and sequenced as previously described <xref ref-type="bibr" rid="pone.0029205-Garin1">[8]</xref>. Additionally, 100 unrelated, non-diabetic individuals were studied, and served as control group.</p>
      </sec>
      <sec id="s3d">
        <title>In silico studies</title>
        <p>The potential effect on mRNA splicing of the c.188-31G&gt;A mutation was analyzed using the splice site prediction of <italic>CBS-Gene Finding and Intron Splice Site Prediction</italic> (<ext-link ext-link-type="uri" xlink:href="http://www.cbs.dtu.dk/services/NetGene2/">http://www.cbs.dtu.dk/services/NetGene2/</ext-link>) web interface.</p>
      </sec>
      <sec id="s3e">
        <title>RNA analysis</title>
        <p>Cell lines were established from peripheral blood lymphocytes derived from the proband and an unaffected control by EBV transformation. Cell lines were maintained in 1&#xD7; RPMI-1640 (Gibco Life Technologies, Paisley, UK), supplemented with 10% fetal calf serum (Gibco Life Technologies, Paisley, UK). Total RNA was extracted from approximately 1&#xD7;10<sup>6</sup> EBV-transformed lymphoblastoid cellsusing QiaAmp Blood RNA mini kit (QIAGEN, D&#xFC;ren, Germany). Synthesis of complementary DNA (cDNA) and amplification of the fragment of interest were performed from mRNA using the One Step RT-PCR (QIAGEN, D&#xFC;ren, Germany) (primers and conditions are available on request). RT-PCR products were run on 4% agarose gels and the amplicons were excised and purified by QIAquick Gel Extraction Kit (QIAGEN; D&#xFC;ren, Germany). The purified amplicons were sequenced by standard methods on an ABI3130XL (Applied Biosystems, Warrington, UK).</p>
      </sec>
      <sec id="s3f">
        <title>Protein Structure Prediction</title>
        <p>3D structure of the mutant protein was predicted using I-TASSER fold recognition method <xref ref-type="bibr" rid="pone.0029205-Zhang1">[19]</xref>. The predicted structure was superimposed with the normal proinsulin structure (PDB ref: 2KQP) using TM-Align <xref ref-type="bibr" rid="pone.0029205-Zhang2">[20]</xref> and visualised with PyMOL Software (<ext-link ext-link-type="uri" xlink:href="http://www.pymol.org">www.pymol.org</ext-link>).</p>
      </sec>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn fn-type="conflict">
        <p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p>
      </fn>
      <fn fn-type="financial-disclosure">
        <p><bold>Funding: </bold>This work was supported by the Centro de Investigaci&#xF3;n Biom&#xE9;dica en Red de Diabetes y Enfermedades Metab&#xF3;licas (CIBERDEM; grant MODIAB) and PI09/1492 from the Instituto de Salud Carlos III of the Spanish Ministry of Health to LC; PI06/0690 from the Instituto de Salud Carlos III of the Spanish Ministry of Health to GPN. IG was supported by FIS-programs I3SNS-I3SNSCA10/01056. GPN is co-funded the Instituto de Salud Carlos III of the Spanish Ministry of Health I3SNS Program (grant CP03/0064; SIVI 1395/09). LWH was funded by the Wellcome Trust (grant number WT081278MA). ORC was funded by a R&#xED;o Hortega Research Fellowship from the Instituto de Salud Carlos III (FIS CM06/00013). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>References</title>
      <ref id="pone.0029205-Russo1">
        <label>1</label>
        <element-citation publication-type="journal">             <person-group person-group-type="author"><name><surname>Russo</surname><given-names>L</given-names></name><name><surname>Iafusco</surname><given-names>D</given-names></name><name><surname>Brescianini</surname><given-names>S</given-names></name><name><surname>Nocerino</surname><given-names>V</given-names></name><name><surname>Bizzarri</surname><given-names>C</given-names></name><etal/></person-group>             <year>2011</year>             <article-title>Permanent diabetes during the first year of life: multiple gene screening in 54 patients.</article-title>             <source>Diabetologia</source>             <volume>54</volume>             <fpage>1693</fpage>             <lpage>1701</lpage>          <pub-id pub-id-type="pmid">21544516</pub-id></element-citation>
      </ref>
      <ref id="pone.0029205-Stoy1">
        <label>2</label>
        <element-citation publication-type="journal">             <person-group person-group-type="author"><name><surname>Stoy</surname><given-names>J</given-names></name><name><surname>Steiner</surname><given-names>DF</given-names></name><name><surname>Park</surname><given-names>SY</given-names></name><name><surname>Ye</surname><given-names>H</given-names></name><name><surname>Philipson</surname><given-names>LH</given-names></name><etal/></person-group>             <year>2010</year>             <article-title>Clinical and molecular genetics of neonatal diabetes due to mutations in the insulin gene.</article-title>             <source>Rev Endocr Metab Disord</source>             <volume>11</volume>             <fpage>205</fpage>             <lpage>215</lpage>          <pub-id pub-id-type="pmid">20938745</pub-id></element-citation>
      </ref>
      <ref id="pone.0029205-Edghill1">
        <label>3</label>
        <element-citation publication-type="journal">             <person-group person-group-type="author"><name><surname>Edghill</surname><given-names>EL</given-names></name><name><surname>Flanagan</surname><given-names>SE</given-names></name><name><surname>Patch</surname><given-names>AM</given-names></name><name><surname>Boustred</surname><given-names>C</given-names></name><name><surname>Parrish</surname><given-names>A</given-names></name><etal/></person-group>             <year>2008</year>             <article-title>Insulin mutation screening in 1,044 patients with diabetes: mutations in the INS gene are a common cause of neonatal diabetes but a rare cause of diabetes diagnosed in childhood or adulthood.</article-title>             <source>Diabetes</source>             <volume>57</volume>             <fpage>1034</fpage>             <lpage>1042</lpage>          <pub-id pub-id-type="pmid">18162506</pub-id></element-citation>
      </ref>
      <ref id="pone.0029205-Colombo1">
        <label>4</label>
        <element-citation publication-type="journal">             <person-group person-group-type="author"><name><surname>Colombo</surname><given-names>C</given-names></name><name><surname>Porzio</surname><given-names>O</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Massa</surname><given-names>O</given-names></name><name><surname>Vasta</surname><given-names>M</given-names></name><etal/></person-group>             <year>2008</year>             <article-title>Seven mutations in the human insulin gene linked to permanent neonatal/infancy-onset diabetes mellitus.</article-title>             <source>J Clin Invest</source>             <volume>118</volume>             <fpage>2148</fpage>             <lpage>2156</lpage>          <pub-id pub-id-type="pmid">18451997</pub-id></element-citation>
      </ref>
      <ref id="pone.0029205-Stoy2">
        <label>5</label>
        <element-citation publication-type="journal">             <person-group person-group-type="author"><name><surname>Stoy</surname><given-names>J</given-names></name><name><surname>Edghill</surname><given-names>EL</given-names></name><name><surname>Flanagan</surname><given-names>SE</given-names></name><name><surname>Ye</surname><given-names>H</given-names></name><name><surname>Paz</surname><given-names>VP</given-names></name><etal/></person-group>             <year>2007</year>             <article-title>Insulin gene mutations as a cause of permanent neonatal diabetes.</article-title>             <source>Proc Natl Acad Sci U S A</source>             <volume>104</volume>             <fpage>15040</fpage>             <lpage>15044</lpage>          <pub-id pub-id-type="pmid">17855560</pub-id></element-citation>
      </ref>
      <ref id="pone.0029205-Molven1">
        <label>6</label>
        <element-citation publication-type="journal">             <person-group person-group-type="author"><name><surname>Molven</surname><given-names>A</given-names></name><name><surname>Ringdal</surname><given-names>M</given-names></name><name><surname>Nordbo</surname><given-names>AM</given-names></name><name><surname>Raeder</surname><given-names>H</given-names></name><name><surname>Stoy</surname><given-names>J</given-names></name><etal/></person-group>             <year>2008</year>             <article-title>Mutations in the insulin gene can cause MODY and autoantibody-negative type 1 diabetes.</article-title>             <source>Diabetes</source>             <volume>57</volume>             <fpage>1131</fpage>             <lpage>1135</lpage>          <pub-id pub-id-type="pmid">18192540</pub-id></element-citation>
      </ref>
      <ref id="pone.0029205-Polak1">
        <label>7</label>
        <element-citation publication-type="journal">             <person-group person-group-type="author"><name><surname>Polak</surname><given-names>M</given-names></name><name><surname>Dechaume</surname><given-names>A</given-names></name><name><surname>Cave</surname><given-names>H</given-names></name><name><surname>Nimri</surname><given-names>R</given-names></name><name><surname>Crosnier</surname><given-names>H</given-names></name><etal/></person-group>             <year>2008</year>             <article-title>Heterozygous missense mutations in the insulin gene are linked to permanent diabetes appearing in the neonatal period or in early infancy: a report from the French ND (Neonatal Diabetes) Study Group.</article-title>             <source>Diabetes</source>             <volume>57</volume>             <fpage>1115</fpage>             <lpage>1119</lpage>          <pub-id pub-id-type="pmid">18171712</pub-id></element-citation>
      </ref>
      <ref id="pone.0029205-Garin1">
        <label>8</label>
        <element-citation publication-type="journal">             <person-group person-group-type="author"><name><surname>Garin</surname><given-names>I</given-names></name><name><surname>Edghill</surname><given-names>EL</given-names></name><name><surname>Akerman</surname><given-names>I</given-names></name><name><surname>Rubio-Cabezas</surname><given-names>O</given-names></name><name><surname>Rica</surname><given-names>I</given-names></name><etal/></person-group>             <year>2010</year>             <article-title>Recessive mutations in the INS gene result in neonatal diabetes through reduced insulin biosynthesis.</article-title>             <source>Proc Natl Acad Sci U S A</source>             <volume>107</volume>             <fpage>3105</fpage>             <lpage>3110</lpage>          <pub-id pub-id-type="pmid">20133622</pub-id></element-citation>
      </ref>
      <ref id="pone.0029205-Raile1">
        <label>9</label>
        <element-citation publication-type="journal">             <person-group person-group-type="author"><name><surname>Raile</surname><given-names>K</given-names></name><name><surname>O'Connell</surname><given-names>M</given-names></name><name><surname>Galler</surname><given-names>A</given-names></name><name><surname>Werther</surname><given-names>G</given-names></name><name><surname>Kuhnen</surname><given-names>P</given-names></name><etal/></person-group>             <year>2011</year>             <article-title>Diabetes caused by insulin gene (INS) deletion: clinical characteristics of homozygous and heterozygous individuals.</article-title>             <source>Eur J Endocrinol</source>             <volume>165</volume>             <fpage>255</fpage>             <lpage>260</lpage>          <pub-id pub-id-type="pmid">21566073</pub-id></element-citation>
      </ref>
      <ref id="pone.0029205-Park1">
        <label>10</label>
        <element-citation publication-type="journal">             <person-group person-group-type="author"><name><surname>Park</surname><given-names>SY</given-names></name><name><surname>Ye</surname><given-names>H</given-names></name><name><surname>Steiner</surname><given-names>DF</given-names></name><name><surname>Bell</surname><given-names>GI</given-names></name></person-group>             <year>2010</year>             <article-title>Mutant proinsulin proteins associated with neonatal diabetes are retained in the endoplasmic reticulum and not efficiently secreted.</article-title>             <source>Biochem Biophys Res Commun</source>             <volume>391</volume>             <fpage>1449</fpage>             <lpage>1454</lpage>          <pub-id pub-id-type="pmid">20034470</pub-id></element-citation>
      </ref>
      <ref id="pone.0029205-Meur1">
        <label>11</label>
        <element-citation publication-type="journal">             <person-group person-group-type="author"><name><surname>Meur</surname><given-names>G</given-names></name><name><surname>Simon</surname><given-names>A</given-names></name><name><surname>Harun</surname><given-names>N</given-names></name><name><surname>Virally</surname><given-names>M</given-names></name><name><surname>Dechaume</surname><given-names>A</given-names></name><etal/></person-group>             <year>2010</year>             <article-title>Insulin gene mutations resulting in early-onset diabetes: marked differences in clinical presentation, metabolic status, and pathogenic effect through endoplasmic reticulum retention.</article-title>             <source>Diabetes</source>             <volume>59</volume>             <fpage>653</fpage>             <lpage>661</lpage>          <pub-id pub-id-type="pmid">20007936</pub-id></element-citation>
      </ref>
      <ref id="pone.0029205-Liu1">
        <label>12</label>
        <element-citation publication-type="journal">             <person-group person-group-type="author"><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Haataja</surname><given-names>L</given-names></name><name><surname>Wright</surname><given-names>J</given-names></name><name><surname>Wickramasinghe</surname><given-names>NP</given-names></name><name><surname>Hua</surname><given-names>QX</given-names></name><etal/></person-group>             <year>2010</year>             <article-title>Mutant INS-gene induced diabetes of youth: proinsulin cysteine residues impose dominant-negative inhibition on wild-type proinsulin transport.</article-title>             <source>PLoS One</source>             <volume>5</volume>             <fpage>e13333</fpage>          <pub-id pub-id-type="pmid">20948967</pub-id></element-citation>
      </ref>
      <ref id="pone.0029205-Faustino1">
        <label>13</label>
        <element-citation publication-type="journal">             <person-group person-group-type="author"><name><surname>Faustino</surname><given-names>NA</given-names></name><name><surname>Cooper</surname><given-names>TA</given-names></name></person-group>             <year>2003</year>             <article-title>Pre-mRNA splicing and human disease.</article-title>             <source>Genes Dev</source>             <volume>17</volume>             <fpage>419</fpage>             <lpage>437</lpage>          <pub-id pub-id-type="pmid">12600935</pub-id></element-citation>
      </ref>
      <ref id="pone.0029205-Cartegni1">
        <label>14</label>
        <element-citation publication-type="journal">             <person-group person-group-type="author"><name><surname>Cartegni</surname><given-names>L</given-names></name><name><surname>Chew</surname><given-names>SL</given-names></name><name><surname>Krainer</surname><given-names>AR</given-names></name></person-group>             <year>2002</year>             <article-title>Listening to silence and understanding nonsense: exonic mutations that affect splicing.</article-title>             <source>Nat Rev Genet</source>             <volume>3</volume>             <fpage>285</fpage>             <lpage>298</lpage>          <pub-id pub-id-type="pmid">11967553</pub-id></element-citation>
      </ref>
      <ref id="pone.0029205-Silva1">
        <label>15</label>
        <element-citation publication-type="journal">             <person-group person-group-type="author"><name><surname>Silva</surname><given-names>AL</given-names></name><name><surname>Romao</surname><given-names>L</given-names></name></person-group>             <year>2009</year>             <article-title>The mammalian nonsense-mediated mRNA decay pathway: to decay or not to decay! Which players make the decision?.</article-title>             <source>FEBS Lett</source>             <volume>583</volume>             <fpage>499</fpage>             <lpage>505</lpage>          <pub-id pub-id-type="pmid">19162024</pub-id></element-citation>
      </ref>
      <ref id="pone.0029205-Vasudevan1">
        <label>16</label>
        <element-citation publication-type="journal">             <person-group person-group-type="author"><name><surname>Vasudevan</surname><given-names>S</given-names></name><name><surname>Peltz</surname><given-names>SW</given-names></name><name><surname>Wilusz</surname><given-names>CJ</given-names></name></person-group>             <year>2002</year>             <article-title>Non-stop decay&#x2013;a new mRNA surveillance pathway.</article-title>             <source>Bioessays</source>             <volume>24</volume>             <fpage>785</fpage>             <lpage>788</lpage>          <pub-id pub-id-type="pmid">12210514</pub-id></element-citation>
      </ref>
      <ref id="pone.0029205-Liu2">
        <label>17</label>
        <element-citation publication-type="journal">             <person-group person-group-type="author"><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Hodish</surname><given-names>I</given-names></name><name><surname>Haataja</surname><given-names>L</given-names></name><name><surname>Lara-Lemus</surname><given-names>R</given-names></name><name><surname>Rajpal</surname><given-names>G</given-names></name><etal/></person-group>             <year>2010</year>             <article-title>Proinsulin misfolding and diabetes: mutant INS gene-induced diabetes of youth.</article-title>             <source>Trends Endocrinol Metab</source>             <volume>21</volume>             <fpage>652</fpage>             <lpage>659</lpage>          <pub-id pub-id-type="pmid">20724178</pub-id></element-citation>
      </ref>
      <ref id="pone.0029205-Fendler1">
        <label>18</label>
        <element-citation publication-type="journal">             <person-group person-group-type="author"><name><surname>Fendler</surname><given-names>W</given-names></name><name><surname>Borowiec</surname><given-names>M</given-names></name><name><surname>Antosik</surname><given-names>K</given-names></name><name><surname>Jaroszewska-Swiatek</surname><given-names>B</given-names></name><name><surname>Szwalkiewicz-Warowicka</surname><given-names>E</given-names></name><etal/></person-group>             <year>2011</year>             <article-title>Paternally inherited proinsulin mutations may result in earlier onset of monogenic diabetes mutation identity effect in monogenic diabetes.</article-title>             <source>Diabetes Care</source>             <volume>34</volume>             <fpage>e9</fpage>          <pub-id pub-id-type="pmid">21193618</pub-id></element-citation>
      </ref>
      <ref id="pone.0029205-Zhang1">
        <label>19</label>
        <element-citation publication-type="journal">             <person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name></person-group>             <year>2008</year>             <article-title>I-TASSER server for protein 3D structure prediction.</article-title>             <source>BMC Bioinformatics</source>             <volume>9</volume>             <fpage>40</fpage>          <pub-id pub-id-type="pmid">18215316</pub-id></element-citation>
      </ref>
      <ref id="pone.0029205-Zhang2">
        <label>20</label>
        <element-citation publication-type="journal">             <person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Skolnick</surname><given-names>J</given-names></name></person-group>             <year>2005</year>             <article-title>TM-align: a protein structure alignment algorithm based on the TM-score.</article-title>             <source>Nucleic Acids Res</source>             <volume>33</volume>             <fpage>2302</fpage>             <lpage>2309</lpage>          <pub-id pub-id-type="pmid">15849316</pub-id></element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
